How to buy Fulcrum Therapeutics stock - 15 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Fulcrum Therapeutics stock

Own Fulcrum Therapeutics stock in just a few minutes.

Fulcrum Therapeutics, Inc is a biotechnology business based in the US. Fulcrum Therapeutics shares (FULC) are listed on the NASDAQ and all prices are listed in US Dollars. Fulcrum Therapeutics employs 73 staff and has a trailing 12-month revenue of around USD$8.8 million.

How to buy shares in Fulcrum Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Fulcrum Therapeutics. Find the stock by name or ticker symbol: FULC. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Fulcrum Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Fulcrum Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Fulcrum Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Fulcrum Therapeutics share price

Use our graph to track the performance of FULC stocks over time.

Fulcrum Therapeutics shares at a glance

Information last updated 2021-04-08.
52-week rangeUSD$7.01 - USD$22.39
50-day moving average USD$12.4777
200-day moving average USD$11.5951
Wall St. target priceUSD$19
PE ratio 267
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-50.401

Buy Fulcrum Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Fulcrum Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Fulcrum Therapeutics under- or over-valued?

Valuing Fulcrum Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Fulcrum Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Fulcrum Therapeutics's P/E ratio

Fulcrum Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 267x. In other words, Fulcrum Therapeutics shares trade at around 267x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Fulcrum Therapeutics financials

Revenue TTM USD$8.8 million
Gross profit TTM USD$-46,839,000
Return on assets TTM -37.3%
Return on equity TTM -77.68%
Profit margin 0%
Book value $4.527
Market capitalisation USD$386.8 million

TTM: trailing 12 months

Shorting Fulcrum Therapeutics shares

There are currently 704,988 Fulcrum Therapeutics shares held short by investors – that's known as Fulcrum Therapeutics's "short interest". This figure is 2% up from 690,946 last month.

There are a few different ways that this level of interest in shorting Fulcrum Therapeutics shares can be evaluated.

Fulcrum Therapeutics's "short interest ratio" (SIR)

Fulcrum Therapeutics's "short interest ratio" (SIR) is the quantity of Fulcrum Therapeutics shares currently shorted divided by the average quantity of Fulcrum Therapeutics shares traded daily (recently around 106333.03167421). Fulcrum Therapeutics's SIR currently stands at 6.63. In other words for every 100,000 Fulcrum Therapeutics shares traded daily on the market, roughly 6630 shares are currently held short.

However Fulcrum Therapeutics's short interest can also be evaluated against the total number of Fulcrum Therapeutics shares, or, against the total number of tradable Fulcrum Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Fulcrum Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Fulcrum Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.03% of the tradable shares (for every 100,000 tradable Fulcrum Therapeutics shares, roughly 30 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Fulcrum Therapeutics.

Find out more about how you can short Fulcrum Therapeutics stock.

Fulcrum Therapeutics share dividends

We're not expecting Fulcrum Therapeutics to pay a dividend over the next 12 months.

Fulcrum Therapeutics overview

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and ß-thalassemia. The company is also discovering drug targets for the treatments of muscle, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site